Navigation Links
CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
Date:1/6/2011

in treatment resistant depression, and we are delighted that our Phase II trial is now enrolling patients," said Daniel Burch, MD, Chief Medical Officer of CeNeRx.  "The new formulation of TriRima has demonstrated excellent safety in multiple studies to date, and we believe that it has the potential to become the first agent to achieve the triple action efficacy of MAO inhibitor drugs without their limiting side effects."

The modified release formulation of TriRima has major advantages over the version used in earlier studies.  In addition to displaying excellent pharmacokinetic properties, the dosing frequency has been reduced to one tablet administered once or twice daily.

"TriRima addresses a large unmet medical need -- currently a substantial proportion of patients with major depression do not receive adequate relief from their therapy," noted Barry Brand, Chief Executive Officer of CeNeRx.  "TriRima has the potential to be the first option that provides these patients superior efficacy and a good safety profile as monotherapy, and we look forward to advancing the Phase II trial in the coming year."

CeNeRx will be presenting at the Biotech Showcase 2011 meeting at 11:00 AM PST on January 11.  The conference is being held January 10-12, 2011 at the Parc 55 Wyndham, San Francisco.   More information on the meeting can be found at www.ebdgroup.com/bts/index.php.

.

About CeNeRx BioPharmaCeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system.  CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment resistant depression.  RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profil
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
5. CeNeRx BioPharma Completes $13 Million Series C Financing
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... and Trademark Office (USPTO) has issued a key ... cell-based immunotherapeutic vaccine targeting six tumor antigens that ... US Patent No. 8,871,211, which issued October 28, ... administering a dendritic cell composition comprising peptide epitopes ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... Texas, June 28, 2011 Pharmacy Choice and ... local businesses and pharmacists across the nation and ... care – applauds the Texas Legislature for the ... critical amendments that provide necessary protections for Texans ...
... RESTON, Va., June 28, 2011 The Mirixa ... Stores (CACDS) are pleased to announce that MirixaPro(SM), ... standardized, pharmacy-based patient care service delivery, will be ... 10-year licensing agreement enabling CACDS to use a ...
Cached Medicine Technology:Pharmacy Choice and Access Now Coalition Applauds Passage of Senate Bill 7 During Texas Legislature's Special Session 2Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 2Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... with PureWellness to Provide Online Wellness Platform to All Employees ... ... 29, 2008 -- PureWellness, Inc, a leading provider of ... agreement with Children,s Healthcare of Atlanta, one of the nation,s ...
... pain-free, CHICAGO, July 29 They danced to ... with Jane Fonda and made,jogging their national pastime., ... aren,t,ready to slow down, even if their bodies are. ... than previous generations to seek care when,arthritis develops in ...
... of Wisconsin researchers in Milwaukee have reported that ... a genetic risk factor for Alzheimer,s disease have ... symptoms may appear. , Functional MRI brain ... APOE-4 gene demonstrated significantly reduced functional brain connectivity ...
... with 360 Health & Safety Violations, SALINAS, Calif., ... Center and Windsor Ridge Care Center will,hold a joint ... resident safety. In 2006, both of these homes made ... will be held,simultaneously at eight Bay Area nursing homes ...
... previously thought, researchers say , , MONDAY, July 28 (HealthDay ... of mild cognitive impairment in the elderly population is ... rate of new mild cognitive impairment cases, in this ... Ronald C. Petersen said in a news release. "If ...
... breathing will become even bigger problem, AHA warns , , ... be conducted to determine the exact link between sleep ... the American Heart Association and the American College of ... Circulation . , "There have been a number ...
Cached Medicine News:Health News:Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program 2Health News:Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program 3Health News:Boomers Not Backing Down From Foot and Ankle Arthritis 2Health News:Boomers Not Backing Down From Foot and Ankle Arthritis 3Health News:Caregivers at 8 Bay Area Nursing Homes Protest Unsafe Resident Conditions in Salinas 2Health News:Rates of Mild Cognitive Impairment Higher Than Expected 2Health News:Rates of Mild Cognitive Impairment Higher Than Expected 3Health News:Experts Urge Research on Sleep Apnea-Heart Disease Link 2
... and Alliance Catheter Delivery System ... introduction of catheters or devices ... a superior approach. These introducers ... peel-away introducer performance with a ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... design and ergonomic handle for easy ... Nitinol markers on the proximal and ... visibility. Corrugated ring design provides flexibility ... ring pattern minimizes stent shortening, provides ...
... catheters comprise the world's broadest line ... procedures. Their advanced catheter design and ... response with a soft, atraumatic tip. ... sizes, Supreme and Response catheters provide ...
Medicine Products: